Pionyr in the News

September 28, 2021

BioCentury / The TREM2 pipeline: Date Byte

April 8, 2021

BioCentury / Macrophage therapies to watch at AACR

June 24, 2020

PharmaPhorum / Gilead to acquire half of cancer biotech Pionyr for $275m

PMLive / Gilead spends $275m on half-share in immuno-oncology firm Pionyr

June 23, 2020

San Francisco Business Times / With potential $1.8 billion deal, Gilead continues rollup of Bay Area cancer drug companies

Fierce Biotech / Gilead pens $1.5B buyout option deal for Pionyr

Xconomy / Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies

Endpoints / Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech

BioWorld / Pionyr’s deal with Gilead could bring in more than $1B

BioCentury / Gilead gains access to tumor myeloid targets via Pionyr partnership

BioSpace / Gilead Continues Expansion into Oncology with Possible $1.75 Billion Deal with Pionyr

BioPharma Dive / Gilead, in latest cancer bet, puts $275M into immunotherapy startup Pionyr

Reuters Financial Post / Gilead to buy 49.9% stake in cancer drug developer for $275 mln

November 6, 2017

BioCentury / Two Faces of Myeloid